Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis
Technology appraisal
Summary (source: NICE)
Reference: TA127
Type: Technology appraisal
Published: 22 August 2007
Last updated: 21 May 2024
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis is technology appraisal TA127, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 22 August 2007. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.